Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
138,100
Employees138,100
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
138,100
Employees138,100

JNJ Key Statistics

Market cap
388.08B
Market cap388.08B
Price-Earnings ratio
28.20
Price-Earnings ratio28.20
Dividend yield
3.04%
Dividend yield3.04%
Average volume
7.95M
Average volume7.95M
High today
$164.19
High today$164.19
Low today
$160.57
Low today$160.57
Open price
$163.52
Open price$163.52
Volume
7.46M
Volume7.46M
52 Week high
$169.99
52 Week high$169.99
52 Week low
$140.68
52 Week low$140.68

JNJ News

Quartz 4d
Johnson & Johnson is the latest pharma giant to court Trump with new investment plans

Johnson & Johnson (JNJ) is joining Eli Lilly (LLY) in attempting to court favor with President Donald Trump by announcing plans to expand its manufacturing foot...

Benzinga 5d
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease

On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offeri...

FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
Benzinga 5d
Johnson & Johnson To Invest $55 Billion In US To Boost Manufacturing, Drug Discovery

Pharmaceutical and medical technology giant Johnson & Johnson JNJ plans to invest more than $55 billion in the U.S. over the next four years. This initiative,...

Johnson & Johnson To Invest $55 Billion In US To Boost Manufacturing, Drug Discovery

Analyst ratings

54%

of 24 ratings
Buy
45.8%
Hold
54.2%
Sell
0%

More JNJ News

Seeking Alpha 5d
Johnson & Johnson to boost U.S. investments to over $55B

Johnson & Johnson (NYSE:JNJ) on Friday announced plans to boost its U.S. investments to more than $55B over the next four years, marking a 25% rise from the pre...

Johnson & Johnson to boost U.S. investments to over $55B
TipRanks 5d
FDA approves Johnson & Johnson’s TREMFYA in Crohn’s disease

The company states: “Johnson & Johnson announced that the FDA has approved TREMFYA, or guselkumab, the first and only IL-23 inhibitor offering both subcutaneous...

Benzinga 5d
Johnson & Johnson's Golden Cross: Technical Momentum Meets Groundbreaking Lung Cancer Breakthrough

Johnson & Johnson JNJ just hit a Golden Cross, a classic bullish technical pattern that signals potential long-term upside. The stock's 50-day simple moving ave...

Johnson & Johnson's Golden Cross: Technical Momentum Meets Groundbreaking Lung Cancer Breakthrough
TipRanks 6d
Johnson & Johnson’s rybrevant plus lazcluze featured in lung cancer presentation

Johnson & Johnson announced that new data from its oncology pipeline will be presented at the 2025 European Lung Cancer Congress, including overall survival res...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.